Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KA2507 in advanced biliary tract cancer
NCT04186156Phase 2Withdrawn
- Sponsor
- Karus Therapeutics
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KA2507 in biliary tract cancer (BTC), sponsored by Karus Therapeutics. Planned start Mar 2020; status: withdrawn.
02
Drugs
KA2507
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04186156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186156.